Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression

American Journal of Physiology - Endocrinology and Metabolism

Volumn 296, Issue 1, 2009, Pages

  Kanazawa, Ippei ^a   Yamaguchi, Toru ^a,b   Yano, Shozo ^a   Yamauchi, Mika ^a   Sugimoto, Toshitsugu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

Author keywords

Adenosine 5 monophosphate protein kinase; Bone mor phogenetic protein 2; Endothelial nitric oxide synthase; Osteoblast; Rho kinase

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENYLATE KINASE; BONE MORPHOGENETIC PROTEIN 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FASUDIL; GERANYLGERANYL PYROPHOSPHATE; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; N(G) NITROARGININE METHYL ESTER; NOGGIN; OSTEOCALCIN; PROTEIN KINASE B; RHO KINASE;

ANIMAL CELL; ARTICLE; BONE MINERALIZATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADENYLATE KINASE; AMINOIMIDAZOLE CARBOXAMIDE; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE REMODELING; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL LINE; ENZYME ACTIVATION; HISTOCYTOCHEMISTRY; MICE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE TYPE III; OSTEOBLASTS; OSTEOCALCIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHO-ASSOCIATED KINASES; RIBONUCLEOTIDES; RNA, MESSENGER;

EID: 58249096196     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.90677.2008     Document Type: Article

References (41)

1. Armour KE, Armour KJ, Gallagher ME, Godecke A, Helfrich MH, Reid DM, Ralston SH. Defective bone formation and anabolic response to exogenous estrogen in mice with targeted disruption of endothelial nitric oxide synthase. Endocrinology 142: 760-766, 2001.
2. Barengolts EI, Berman M, Kukreja SC, Kouznetsova T, Lin C, Chomka EV. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int 62: 209-213, 1998.
3. Beg ZH, Allman DW, Gibson DM. Modulation of 3-hydroxy-3-methyl- glutaryl coenzyme A reductase activity with cAMP and wth protein fractions of rat liver cytosol. Biochem Biophys Res Commun 54: 1362-1369, 1973.
4. Browner WS, Pressman AR, Nevitt MC, Cauley JA, Cummings SR. Association between low bone density and stroke in elderly women. The study of osteoporotic fractures. Stroke 24: 940-946, 1993.
5. Carling D. The AMP-activated protein kinase cascade-a unifying system for energy control. Trends Biochem Sci 29: 18 -24, 2004.
6. Corton JM, Gillespie JG, Hawley SA, Hardie DG. 5-Aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur J Biochem 229: 558-565, 1995.
7. Frye MA, Melton LJ 3rd, Bryant SC, Fitzpatrick LA, Wahner HW, Schwartz RS, Riggs BL. Osteoporosis and calcification of the aorta. Bone Miner 19: 185-194, 1992.
8. Fujii N, Aschenbach WG, Musi N, Hirshman MF, Goodyear LJ. Regulation of glucose transport by the AMP-activated protein kinase. Proc Nutr Soc 63: 205-210, 2004.
9. Fujita T, Okamoto Y, Sakagami Y, Ota K, Ohata M. Bone changes and aortic calcification in aging inhabitants of mountain versus seacoast communities in the Kii Peninsula. J Am Geriatr Soc 32: 124-128, 1984.
10. Garret IR, Gutierrez G, Mundy GR. Statins and bone formation. Curr Pharm Des 7: 715-736, 2001.
11. Giri S, Nath N, Smith B, Viollet B, Singh AK, Singh I. 5-Aminoim-idazole-4-carboxamide-1-beta-4-ribofuranoside inhibits proinflammatory response in glial cells: a possible role of AMP-activated protein kinase. J Neurosci 24: 479-487, 2004.
12. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 343: 425-430, 1990.
13. Hardie DG, Carling D. The AMP-activated protein kinase: fuel gauge of the mammalian cell? Eur J Biochem 246: 259-273, 1997.
14. Hardie DG, Scott JW, Pan DA, Hudson ER. Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett 546: 113-120, 2003.
15. Harmey D, Stenbeck G, Nobes CD, Lax AJ, Grigoriadis AE. Regulation of osteoblast differentiation by Pasteurella multocida toxin (PMT): a role for Rho GTPase in bone formation. J Bone Miner Res 19: 661-670, 2004.
16. Higuchi C, Myoui A, Hashimoto N, Kuriyama K, Yoshioka K, Yo-shikawa H, Itoh K. Continuous inhibition of MAPK signaling promotes the early osteoblastic differentiation and mineralization of the extracellular matrix. J Bone Miner Res 17: 1785-1794, 2002.
17. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25, 2005.
18. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells. BMC Cell Biol 8: 51-62, 2007.
19. Kefas BA, Cai Y, Ling Z, Heimberg H, Hue L, Pipeleers D, Van de Casteele M. AMP-activated protein kinase can induce apoptosis of insulin-producing MIN 6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol 30: 151-161, 2003.
20. Kefas BA, Heimberg H, Vaulont S, Meisse D, Hue L, Pipeleers D, Van de Casteele M. AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase. Diabetologia 46: 250-254, 2003.
21. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89: 2548-2556, 2004.
22. Kim JE, Ahn MW, Baek SH, Lee IK, Kim YW, Kim JY, Dan JM, Park SY. AMPK activator, AICAR, inhibits palmitate-induced apoptosis in osteoblast. Bone 43: 394-404, 2008.
23. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, Walsh K. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholester-olemic animals. Nat Med 6: 1004-1010, 2000.
24. Lai CF, Chaudhary L, Fausto A, Halstead LR, Ory DS, Avioli LV, Cheng SL. Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells. J Biol Chem 276: 14443-14450, 2001.
25. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3- methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of en-dothelial nitric oxide syntase. J Biol Chem 272: 31725-31729, 1997.
26. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide syntase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271, 1998.
27. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] method. Methods 25: 402-408, 2001.
28. Lowry OH, Roberts NR, Wu ML, Hixon WS, Crawford EJ. The quantitative histochemistry of brain. II. Enzyme measurements. J Biol Chem 207: 19-37, 1954.
29. Meyers VE, Zayzafoon M, Douglas JT, McDonald JM. RhoA and cytoskeletal disruption mediate reduced osteoblastogenesis and enhanced adipogenesis of human mesenchymal stem cells in modeled microgravity. J Bone Miner Res 20: 1858-1866, 2005.
30. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 286: 1946-1949, 1999.
31. Ohnaka K, Shimoda S, Nawata H, Shimokawa H, Kaibuchi K, Iwamoto Y, Takayanagi R. Pitavastatin enhanced BMP-2 and osteocal-cin expression by inhibition of Rho-associated kinase in human osteo-blasts. Biochem Biophys Res Commun 287: 337-342, 2001.
32. Ouchi Y, Akishita M, de Souza AC, Nakamura T, Orimo H. Age-related loss of bone mass and aortic/aortic valve calcification-reevaluation of recommended dietary allowance of calcium in the elderly. Ann NY Acad Sci 676: 297-307, 1993.
33. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 39: 319-327, 2002.
34. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 25:1767-1775, 2005.
35. Sowa H, Kaji H, Yamaguchi T, Sugimoto T, Chihara K. Smad3 promotes alkaline phosphatase activity and mineralization of osteoblastic MC3T3-E1 cells. J Bone Miner Res 17: 1190-1199, 2002.
36. Sudo H, Kodama HA, Amagai Y, Yamamoto S, Kassai S. In vitro differentiation and calcification in a new clonal osteogenic cell line derived from newborn mouse calvaria. J Cell Biol 96: 191-198, 1983.
37. Vogt MT, San Valentin R, Forrest KY, Nevitt MC, Cauley JA. Bone mineral density and aortic calcification: the study of osteoporotic fractures. J Am Geriatr Soc 45: 140-145, 1997.
38. von der Recke P, Hansen MA, Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 106: 273-278, 1999.
39. Yamaguchi T, Sugimoto T, Yano S, Yamauchi M, Sowa H, Chen Q, Chihara K. Plasma lipids and osteoporosis in postmenopausal women. Endocr. J 49: 211-217, 2002.
40. Yamauchi M, Yamaguchi T, Kaji H, Sugimoto T, Chihara K. Involvement of calcium-sensing receptor in osteoblastic differentiation of mouse MC3T3-E1 cells. Am J Physiol Endocrinol Metab 288: E608-E616, 2005.
41. Yano S, Mentaverri R, Kanuparthi D, Bandyopadhyay S, Riverda A, Brown EM, Chattopadhyay N. Functional expression of beta-chemokine receptors in osteoblasts: role of regulated upon activation, normal T cell expressed and secreted (RANTES) in osteoblasts and regulation of its secretion by osteoblasts and osteoclasts. Endocrinology 146: 2324-2335, 2005.